The Effects of Intranasal Oxytocin on Reward Sensitivity and Performance Monitoring During Reinforcement Learning: an ERP Study
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Neural index: Event-related potential: Feedback Related Negativity (FRN) during acquisition phase
研究概览
简要总结
The main aim of the study is to investigate whether intranasal oxytocin (24IU) influences reward sensitivity and performance monitoring during reinforcement learning.
详细描述
A double-blind, within-subject, placebo-controlled pharmacological EEG design will be employed. A total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24IU) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent EEG acquisition. During the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). The paradigm includes an initial acquisition phase and a subsequent test phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 30 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age between 18-30
- •Right handedness
排除标准
- •History of brain injury
- •Current or history of psychiatric, neurological or internist disorder
- •Current or regular use of medication, psychotropic substances, including nicotine
- •Contraindications for Oxytocin
研究组 & 干预措施
Oxytocin then placebo
Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
干预措施: intranasal oxytocin (Drug)
Oxytocin then placebo
Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
干预措施: intranasal placebo (Drug)
Placebo then oxytocin
Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
干预措施: intranasal oxytocin (Drug)
Placebo then oxytocin
Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
干预措施: intranasal placebo (Drug)
结局指标
主要结局
Neural index: Event-related potential: Feedback Related Negativity (FRN) during acquisition phase
时间窗: 45-105 minutes after treatment administration
Feedback Related Negativity (FRN): a negative ERP component evoked by negative feedback relative to positive feedback during the acquisition phase will be compared between the oxytocin and placebo treatment conditions.
Neural index: Event-related potential: Error Related Negativity (ERN) during the test phase
时间窗: 45-105 minutes after treatment administration
Error Related Negativity (ERN): a negative ERP component evoked by incorrect responses relative to correct responses during the test phase will be compared between the oxytocin and placebo treatment conditions.
次要结局
- Behavioral index: Response accuracy to superior stimuli during the acquisition phase(45-105 minutes after treatment administration)
- Response accuracy avoiding stimuli associated with higher probability negative feedback in the test phase.(45-105 minutes after treatment administration)
- Response accuracy in response to superior stimuli associated with relative higher probability positive feedback in the test phase.(45-105 minutes after treatment administration)
- Behavioral index: Response accuracy to stimuli associated with highest probability positive feedback during the test phase(45-105 minutes after treatment administration)
- Response accuracy avoiding stimuli associated with highest probability negative feedback in the test phase.(45-105 minutes after treatment administration)
研究者
Keith Kendrick
Professor
University of Electronic Science and Technology of China